Q4 2025 earnings call: nsPFA clinical/regulatory timeline, Vybrance rollout, revenue trends, cash burn & outlook—read now.

Long-term VBC success hinges on robust data integrity and seamless integration across clinical, claims, government and personal health data sources.

Two separate non-GLP studies in mice and non-human primates (NHPs) assessed the safety and tolerability of CUE-401 using a ...

A practising cardiologist has built a patient care application in seven days and secured third place at a hackathon run by artificial intelligence firm Anthropic, a result that is drawing fresh ...

Memorial Sloan Kettering's enterprise architecture chief offers practical advice for getting ahold of this fast-growing challenge before it overwhelms storage and cost-management strategies.

Q4 2025 earnings call recap: revenue/EBITDA growth, 2026 guidance, AMDS & NEXUS trial/regulatory updates, and key risks—read now.

Transparency Scorecard to increase visibility into non-clinical dimensions of MA plan performance that fall outside the appropriate scope of Star Ratings.

Zealand Pharma achieved notable organizational growth in 2025, with a 41% increase in the number of employees compared to 2024. Despite this rapid expansion, the company improved its high employee ...

Bipolar I disorder is a lifelong illness, with outcomes shaped by many variable factors, any one or a combination of which ...

MINNEAPOLIS, MN, UNITED STATES, January 20, 2026 /EINPresswire.com/ -- Itiliti Health, a leader in prior authorization ...